Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

By D. Graham, J. Staffa, D. Shatin, S. Andrade, Stephanie D. Schech, L. La Grenade, J. Gurwitz, K. Chan, Michael J. Goodman, R. Platt. Journal of the American Medical Association (JAMA), 2004

896 citations recorded by the source corpus.

Subfields: Emergency Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/1c5072a58527c979c32d24907fe0cca82e080cd4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. I. Graham
2. Marja-Riitta Taskinen
3. Alberico L. Catapano
4. Ulrich Laufs

Citations in the corpus

• Type 2 diabetes in children and adolescents (2003, neutral): “Comorbidities characteristic of the insulin resistance syndrome are commonly seen at diagnosis or appear early in the course of T2DM and should be tested for sooner than in T1DM, where these disorders are complications of the diabetes rather than comorbid conditions (70, 71) (B).”
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Gemfibrozil inhibits the metabolism of statins via the glucuronidation pathway, which leads to marked increases in plasma concentrations of statins.(320) As fenofibrate does not share the same pharmacokinetic pathways as gemfibrozil, the risk of myopathy is much less with this combination therapy.”
• Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, neutral): “Muscle) was discovered through case reports, not clinical trials, because statin-induced rhabdomyolysis is rare, but the background rate of idiopathic rhabdomyolysis is rarer still.(23) There are occasional specific situations in which RCTs are not ethical or are impractical.”
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake (2011, background): “The clinical spectrum of statin-induced myopathy ranges from a mild and relatively common myalgia (5–10% of statin users/year) to a life-threatening and rare rhabdomyolysis (0.001–0.005% of statin users/year) (Staffa et al., 2002; Graham et al., 2004).”